Fig. 6: CTX-neutralizing capacity of BL3.2 in infant mice.
From: Orally delivered toxin–binding protein protects against diarrhoea in a murine cholera model
a Schematic representation of the two oral administrations of BL3.2 given to 5-day-old CD-1 mice (Charles River Laboratories, strain 022, mixed sex); 1 h before and 3 h after CTX administration. Created using BioRender. Laboratory, T. (2025) https://BioRender.com/c95v770. b Impact of the orally delivered VHH construct BL3.2 on the severity of CTX-associated diarrhoea (weight loss) in infant mice. Mice were given two oral administrations of either BL3.2 (n = 5, 9 mg ml−1) or bovine serum albumin (BSA) as a control (n = 5, 9 mg ml−1); one 3 h prior to oral delivery of CTX and one 3 h after oral delivery of CTX. diarrhoeal onset (red) or diarrhoeal absence (white) was visually monitored up until the experiment was terminated, 9 h following CTX administration. Horizontal lines indicate median weight loss for BL3.2 (0.53%) and BSA (3.8%), and statistical significance (*p < 0.05) was calculated using the two-tailed Mann–Whitney U test (P = 0.0317). Source data are provided in a Source Data file. c Impact of the orally delivered bivalent VHH construct BL3.2 on CTX-induced fluid accumulation (FA) in the small intestine of infant mice. Mice were given two oral administrations of either BL3.2 (n = 5, 9 mg ml−1) or BSA as a control (n = 5, 9 mg ml−1), as previously described. Statistical difference (**P < 0.01) between median FA ratio (horizontal line) for BL3.2 (5.5%) and BSA (9.8%) was calculated using the two-tailed Mann–Whitney U test (P = 0.0079). Source data are provided in a Source Data file.
